Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes

To assess whether the effects of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors on cardiovascular, kidney and mortality outcomes are consistent with and without concomitant metformin use.

[1]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[2]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[3]  D. DeMets,et al.  Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy , 2020, Diabetes Care.

[4]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[5]  Deepak L. Bhatt,et al.  Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58 , 2020, Diabetes, obesity & metabolism.

[6]  C. Mathieu,et al.  Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) , 2020, Diabetologia.

[7]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. , 2020, JAMA.

[8]  C. Cannon,et al.  Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis , 2020, Journal of the American Heart Association.

[9]  I. Campbell,et al.  Metformin and cardiorenal outcomes in diabetes: A reappraisal , 2019, Diabetes, obesity & metabolism.

[10]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[11]  A. Levin,et al.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.

[12]  M. Jardine,et al.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering , 2019, Canadian Medical Association Journal.

[13]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[14]  B. Zinman,et al.  Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy? , 2019, Diabetes, obesity & metabolism.

[15]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[16]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[17]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[18]  K. Khunti,et al.  Should sodium‐glucose co‐transporter‐2 inhibitors be considered as first‐line oral therapy for people with type 2 diabetes? , 2018, Diabetes, obesity & metabolism.

[19]  Vertis-Cv Investigators.  Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV) , 2018 .

[20]  W. Kernan,et al.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.

[21]  S. Griffin,et al.  Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes , 2017, Diabetologia.

[22]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[23]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[24]  F. Gueyffier,et al.  Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials , 2012, PLoS medicine.

[25]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[26]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.